SCHEMBL2240392

SCHEMBL2240392

[O-][N+](=Cc1ccccc1)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
G6PD P11413 4/20 1.00
ALDH1A1 P00352 8/20 0.68
MAPT P10636 8/20 0.68
NPC1 O15118 5/20 0.68
ALOX15 P16050 2/20 0.56
TSHR P16473 2/20 0.56
RECQL P46063 1/20 0.56
HSP90AA1 P07900 1/20 0.54
RAB9A P51151 4/20 0.47
HSD17B10 Q99714 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
CYP1A2 P05177 1/20 0.38
FBP1 P09467 3/20 0.37
CYP1B1 Q16678 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12355268 1.00 G6PD (1.00) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL11404350 0.92 G6PD (0.85) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL12416931 0.92 G6PD (0.85) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL11414227 0.90 ALDH1A1 (0.81) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL264278 0.85 ALDH1A1 (0.73) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL12349218 0.85 ALDH1A1 (0.73) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL264277 0.85 ALDH1A1 (0.73) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL11421824 0.85 G6PD (0.73) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL11404029 0.83 G6PD (0.71) G6PDALDH1A1MAPTNPC1ALOX15
SCHEMBL11409665 0.82 G6PD (0.70) G6PDALDH1A1MAPTNPC1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4224340-A Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds WILLIAM H. RORER, INC. (US) 1980-09-23 US claimed
US-4153722-A ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE WILLIAM H. RORER, INC. (US) 1979-05-08 US claimed
CN-110981808-B Method for synthesizing diastereomer 2-imidazolone compound by silver and alkali concerted catalysis 山东师范大学 2021-01-08 CN disclosed
EP-2265620-B1 SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS COUNCIL SCIENT IND RES (IN) 2014-06-18 EP disclosed
US-8609858-B2 Spiro derivatives of parthenin as novel anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-12-17 US disclosed
US-20110201661-A1 Spiro Derivatives of Parthenin as Novel Anticancer Agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2011-08-18 US disclosed
EP-2265620-A1 SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2010-12-29 EP disclosed
WO-2009110007-A1 SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS COUNCIL QF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-09-11 WO disclosed
US-4224340-A Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds WILLIAM H. RORER, INC. (US) 1980-09-23 US disclosed
US-4214003-A ANTIINFLAMMATORY AGENTS WILLIAM H. RORER, INC. (US) 1980-07-22 US disclosed
US-4197314-A WITH A DIPHENYL NITRONE WILLIAM H. RORER, INC. (US) 1980-04-08 US disclosed
US-4153722-A ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE WILLIAM H. RORER, INC. (US) 1979-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201661-A1 Spiro Derivatives of Parthenin as Novel Anticancer Agents CDK10, NEK10, AKR1B10 G6PD 3468/4885ALDH1A1 1855/4885MAPT 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.